Previous article Next article

The UK Court of Appeal provides guidances regarding the legal test to determine whether pricing is excessive and unfair in the pharmaceutical market (Flynn Pharma / Pfizer)

The UK Court of Appeal Clarifies the Legal Test for Excessive Pricing* Under Article 102 of the Treaty on the Functioning of the European Union (“TFEU”), an undertaking may abuse its dominant position by “directly or indirectly imposing unfair purchase or selling prices”. The UK Court of Appeal recently provided guidance regarding the legal test to determine whether pricing is excessive and unfair. In March, it dismissed the UK Competition and Markets Authority’s (“CMA”) appeal in the Phenytoin case. Background Phenytoin sodium is a prescription anti-epilepsy drug available in a variety of forms, including capsules and tablets. Phenytoin sodium capsules were manufactured and sold by Pfizer Limited (“Pfizer”) under the brand name “Epanutin” in the UK. In 2012, Pfizer transferred the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Covington & Burling (Brussels)
  • Covington & Burling (Brussels)

Quotation

Miranda Cole, Wesley Lepla, The UK Court of Appeal provides guidances regarding the legal test to determine whether pricing is excessive and unfair in the pharmaceutical market (Flynn Pharma / Pfizer), 10 March 2020, e-Competitions Preview, Art. N° 94683

Visites 28

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues